ArticleLeukemia2012

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.

H Pfeifer et al.PubMed ↗Publisher ↗

No numbers read from the abstract.